Navigation Links
Immunomic Therapeutics Engages Newport Coast Securities, Inc.

Hershey, PA & Rockville, MD (PRWEB) July 29, 2014

July 29, 2014 - Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in the biotechnology industry, announced that it has engaged the financial services firm Newport Coast Securities, Inc. to explore financing opportunities that build shareholder value.

ITI is commercializing LAMP-vax technology, a breakthrough vaccine platform with the potential to transform the $25B+ vaccines and immunotherapy market. The company exclusively licensed the well-established LAMP platform from Johns Hopkins University in 2006. The company executed a strategy to build value and maximize return for investors, using a lean team of biotechnology professionals and scientists.

ITI has quickly emerged as a clinical stage company on the cusp of its third commercial out-license. It has done so by applying LAMP to allergy immunotherapy, a large and unmet therapeutic area with shorter timelines and more affordable clinical validation.
Since its inception, ITI has raised over $10M through the support of private investors.

"Our private investors have provided financial investments critical to our growth, and expertise in the biotech realm,” said William Hearl, ITI President and CEO. “We’re now at an inflection point and preparing for more aggressive growth. We are pleased to bring Newport Coast on board as our partner to help us fund and accelerate this growth.”

“Together, we will expand the applications and clinical development of LAMP products, out-license and collaborate with pharmaceutical companies, and build and maximize shareholder value,” Hearl said. “We look forward to continuing ITI’s mission to pioneer vaccines that will transform human life, while creating and building shareholder value.”

A platform biotech company, ITI's business model is to develop products to proof-of-concept, out-license them, and seek early-stage collaborations around LAMP vaccine programs. Its first product is a vaccine for the Japanese red cedar allergy. Phase I clinical trials showed excellent safety and immune responses, and the company is targeting business development opportunities with pharmaceutical companies in Japan. Now in advanced stages of Term Sheet negotiation, a deal is expected in 2015.

Comparables for the product range from $200M - $1B. This initial license, combined with current and planned fundraising with Newport Coast Securities, will validate the platform and non-dilutive funding for subsequent clinical development and out-license in other areas of pollen allergy, food allergy, oncology and animal health.

Dr. William Hearl will embark on a roadshow with Newport to showcase the company’s technology, report on its progress, and share future plans to the private and institutional investment community. The tour starts in August 2014.

About Newport Coast Securities, Inc.
Newport Coast Securities Inc., member FINRA/SIPC, is a full-service firm offering quality investment banking and distribution services to high quality small cap companies. Newport Coast is committed to long-term partnerships with emerging growth companies and the investors who back them. Newport Coast Securities Inc. offers a complete range of brokerage and investment banking services to small cap companies including public offerings, private placements, and M&A advisory, as well as a full range of brokerage and investment services to both institutional and private investors.

About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit or contact Kristi Hughes at MKJ Creative khughes(at)

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
2. String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):